The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $733,624 in first-year total cost, median $366,812.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-M (11)]1
- Special Emphasis Panel[ZRG1 RPHB-R (12)]1
Most frequent institutions
- COPLEX THERAPEUTICS, LLC1
- HEARTHSTONE ALZHEIMER CARE, LTD1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Commercialization of a Novel Therapeutic for Alzheimer's Disease2R42AG044187-02A1 | LOVELL, MARK ANTHONY | COPLEX THERAPEUTICS, LLC, KY | $508,624 | ZRG1 |
| 2017 | My MESSAGE: Improving Wayfinding and Reducing Challenging Behaviors in Persons with Dementia Through the Use of RFID Technology1R41AG056230-01 | ALBRIGHT, THOMAS DGEPSHTEIN, SERGEIZEISEL, JOHN | HEARTHSTONE ALZHEIMER CARE, LTD, MA | $225,000 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.